AngioDynamics Reaffirmed Neutral
We retain our Neutral recommendation for therapeutic and diagnostic devices maker AngioDynamics (NASDAQ:ANGO). Its first-quarter fiscal 2012 adjusted earnings of 8 cents a share matched the Zacks Consensus Estimate. Revenues rose 6% year over year to $54.4 million, but missed the Zacks Consensus Estimate. Profit slipped 27% year over year on account of charges associated [...]
We retain our Neutral recommendation for therapeutic and diagnostic devices maker AngioDynamics (NASDAQ:ANGO). Its first-quarter fiscal 2012 adjusted earnings of 8 cents a share matched the Zacks Consensus Estimate. Revenues rose 6% year over year to $54.4 million, but missed the Zacks Consensus Estimate.
Profit slipped 27% year over year on account of charges associated with the CEO’s departure and the closure of the company’s U.K. facility. Sustained double-digit growth at the Oncology business … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards